Lilly slows FDA submission of Alzheimer's drug after Medicare decision

Eli Lilly is pushing back the timing for when it expects to finish submitting an application for U.S. approval of its experimental drug for Alzheimer's disease, revealing Thursday it now will complete the filing to the Food and Drug Administration by the end of the year, rather than by the end of March.